Comparative Pharmacology
Head-to-head clinical analysis: GEOCILLIN versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEOCILLIN versus VERSAPEN.
GEOCILLIN vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Geocillin (carbenicillin indanyl sodium) is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible gram-negative and gram-positive bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
250-500 mg orally every 6 hours.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
1.2 hours (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Primarily renal (70-80% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal (<5%).
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic